The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Consensus on biomarkers for neuroendocrine tumour disease
Open accessAbstract
Management of neuroendocrine neoplasia represents a clinical challenge because of its late presentation, lack of treatment options, and limitations in present imaging modalities and biomarkers to guide management. Monoanalyte biomarkers have poor sensitivity, specificity, and predictive ability. A National Cancer Institute summit, held in 2007, on neuroendocrine tumours noted biomarker limitations to be a crucial unmet need in the management of neuroendocrine tumours. A multinational consensus meeting of multidisciplinary experts in neuroendocrine tumours assessed the use of current biomarkers and defined the perquisites for novel biomarkers via the Delphi method. Consensus (at >75%) was achieved for 88 (82%) of 107 assessment questions. The panel concluded that circulating multianalyte biomarkers provide the highest sensitivity and specificity necessary for minimum disease detection and that this type of biomarker had sufficient information to predict treatment effectiveness and prognosis. The panel also concluded that no monoanalyte biomarker of neuroendocrine tumours has yet fulfilled these criteria and there is insufficient information to support the clinical use of miRNA or circulating tumour cells as useful prognostic markers for this disease. The panel considered that trials measuring multianalytes (eg, neuroendocrine gene transcripts) should also identify how such information can optimise the management of patients with neuroendocrine tumours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
the delphi method: techniques and applications
Linstone, H. A., & Turoff, M. (1975) · Bibliothèque et Archives nationales du Québec (Québec government) · Cited by 6,590
Yao, J. C., Hassan, M., Phan, A., Dagohoy, C., Leary, C., Mares, J. E., Abdalla, E. K., Fleming, J. B., Vauthey, J.-N., Rashid, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4377 · Cited by 4,510
The Delphi technique: myths and realities
Powell, C. (2003) · Journal of Advanced Nursing · doi:10.1046/j.1365-2648.2003.02537.x · Cited by 2,584
Gastroenteropancreatic neuroendocrine tumours
Modlin, I. M., Oberg, K., Chung, D. C., Jensen, R. T., de Herder, W. W., Thakker, R. V., Caplin, M., Delle Fave, G., Kaltsas, G. A., Krenning, E. P., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70410-2 · Cited by 1,748
Self-citationKlimstra, D. S., Modlin, I. R., Coppola, D., Lloyd, R. V., & Suster, S. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181ec124e · Cited by 1,072
Self-citationGastrointestinal Neuroendocrine Tumors: Pancreatic Endocrine Tumors
Metz, D. C., & Jensen, R. T. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.05.047 · Cited by 816
Self-citationClinical biomarkers in drug discovery and development
Frank, R., & Hargreaves, R. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1130 · Cited by 794
Roldo, C., Missiaglia, E., Hagan, J. P., Falconi, M., Capelli, P., Bersani, S., Calin, G. A., Volinia, S., Liu, C.-G., Scarpa, A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.5194 · Cited by 775
The Delphi Method: Techniques and Applications.
Moore, P. G., Lingstone, H. A., & Turoff, M. (1977) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344913 · Cited by 618
Cited by
Luo, P., Yin, P., Hua, R., Tan, Y., Li, Z., Qiu, G., Yin, Z., Xie, X., Wang, X., Chen, W., et al. (2018) · Hepatology · doi:10.1002/hep.29561 · Cited by 370
Hicks, R. J., Kwekkeboom, D. J., Krenning, E., Bodei, L., Grozinsky-Glasberg, S., Arnold, R., Borbath, I., Cwikla, J., Toumpanakis, C., Kaltsas, G., et al. (2017) · Neuroendocrinology · doi:10.1159/000475526 · Cited by 336
Self-citationMultiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy
Yang, K. S., Im, H., Hong, S., Pergolini, I., del Castillo, A. F., Wang, R., Clardy, S., Huang, C.-H., Pille, C., Ferrone, S., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3226 · Cited by 277
Marotta, V., Zatelli, M. C., Sciammarella, C., Ambrosio, M. R., Bondanelli, M., Colao, A., & Faggiano, A. (2018) · Endocrine-Related Cancer · doi:10.1530/erc-17-0269 · Cited by 161
on behalf of, N. I. K. E., Fanciulli, G., Ruggeri, R. M., Grossrubatscher, E., Calzo, F. L., Wood, T. D., Faggiano, A., Isidori, A., & Colao, A. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09547-8 · Cited by 47
Metadata
- Authors
- Oberg, K., Modlin, I. M., De Herder, W., Pavel, M., Klimstra, D., Frilling, A., Metz, D. C., Heaney, A., Kwekkeboom, D., Strosberg, J., Meyer, T., Moss, S. F., Washington, K., Wolin, E., Liu, E., & Goldenring, J.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2015-09
- Volume
- 16
- Issue
- 9
- Pages
- e435-e446
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2167407589
- Cited by
- 283
- References
- 56
- FWCI
- 18.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Consensus on biomarkers for neuroendocrine tumour disease. https://app.cochat.ai/papers/10.1016/s1470-2045(15)00186-2
- The paper
- Oberg, K., Modlin, I. M., De Herder, W., Pavel, M., Klimstra, D., Frilling, A., Metz, D. C., Heaney, A., Kwekkeboom, D., Strosberg, J., Meyer, T., Moss, S. F., Washington, K., Wolin, E., Liu, E., & Goldenring, J. (2015). Consensus on biomarkers for neuroendocrine tumour disease. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(15)00186-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.